These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. Brunner HI; Chen C; Bovis F; De Benedetti F; Espada G; Joos R; Akikusa J; Chaitow J; Boteanu AL; Kimura Y; Rietschel C; Siri D; Smolewska E; Schmeling H; Brown DE; Martini A; Lovell DJ; Huang B; Ruperto N; Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1264-1274. PubMed ID: 32702212 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Yokota S; Imagawa T; Mori M; Miyamae T; Aihara Y; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T Lancet; 2008 Mar; 371(9617):998-1006. PubMed ID: 18358927 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F; Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358 [TBL] [Abstract][Full Text] [Related]
9. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Garnero P; Thompson E; Woodworth T; Smolen JS Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425 [TBL] [Abstract][Full Text] [Related]
10. Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. Mallalieu NL; Wimalasundera S; Hsu JC; Douglass W; Wells C; Penades IC; Cuttica R; Huppertz HI; Joos R; Kimura Y; Milojevic D; Rosenkranz M; Schikler K; Constantin T; Wouters C Pediatr Rheumatol Online J; 2019 Aug; 17(1):57. PubMed ID: 31438986 [TBL] [Abstract][Full Text] [Related]
11. Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience. Demir S; Sönmez HE; Arslanoğlu-Aydın E; Özen S; Bilginer Y Turk J Pediatr; 2019; 61(2):180-185. PubMed ID: 31951328 [TBL] [Abstract][Full Text] [Related]
12. Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis. Frampton JE Paediatr Drugs; 2013 Dec; 15(6):515-31. PubMed ID: 24155139 [TBL] [Abstract][Full Text] [Related]
13. Radiologic analysis of the effect of tocilizumab on hands and large joints in children with systemic juvenile idiopathic arthritis. Inaba Y; Ozawa R; Aoki C; Imagawa T; Mori M; Hara R; Miyamae T; Saito T; Yokota S Mod Rheumatol; 2013 Jul; 23(4):667-73. PubMed ID: 22791270 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial. Li C; Tang X; Zhou Z; Sun L; Lu M; Zhou W; Yang S; Zheng W; Yu H; Tan W; Zhang J; Zhang Y; Kong Y; Xu J Clin Rheumatol; 2024 Nov; 43(11):3457-3467. PubMed ID: 39279018 [TBL] [Abstract][Full Text] [Related]
15. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Herlin T Expert Rev Clin Immunol; 2012 Aug; 8(6):517-25. PubMed ID: 22992145 [TBL] [Abstract][Full Text] [Related]
16. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis. Aoki C; Inaba Y; Choe H; Kaneko U; Hara R; Miyamae T; Imagawa T; Mori M; Oba MS; Yokota S; Saito T J Rheumatol; 2014 Jun; 41(6):1171-7. PubMed ID: 24786929 [TBL] [Abstract][Full Text] [Related]
17. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205 [TBL] [Abstract][Full Text] [Related]
18. Growth hormone increases final height in patients with juvenile idiopathic arthritis: data from a randomized controlled study. Bechtold S; Ripperger P; Dalla Pozza R; Bonfig W; Häfner R; Michels H; Schwarz HP J Clin Endocrinol Metab; 2007 Aug; 92(8):3013-8. PubMed ID: 17535995 [TBL] [Abstract][Full Text] [Related]
19. Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. Simon D; Prieur AM; Quartier P; Charles Ruiz J; Czernichow P J Clin Endocrinol Metab; 2007 Jul; 92(7):2567-73. PubMed ID: 17488793 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study. Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]